Automated Selection Of Keeper Images From A Burst Photo Captured Set

Systems and methods for improving automatic selection of keeper images from a commonly captured set of images are described. A combination of image type identification and image quality metrics may be used to identify one or more images in the set as keeper images. Image type identification may be used to categorize the captured images into, for example, three or more categories. The categories may include portrait, action, or “other.” Depending on the category identified, the images may be analyzed differently to identify keeper images. For portrait images, an operation may be used to identify the best set of faces. For action images, the set may be divided into sections such that keeper images selected from each section tell the story of the action. For the “other” category, the images may be analyzed such that those having higher quality metrics for an identified region of interest are selected. 1. A non-transitory program storage device , readable by a programmable control device and comprising instructions stored thereon to cause one or more programmable control devices to:obtain a temporal sequence of images of a scene;determine, for each of the obtained images, at least one quality metric value;detect if the scene in the temporal sequence of images contains action;divide the temporal sequence of images into two or more sections, in response to determination that the scene contains action;compare the quality metric values of images within each section; andselect, for each of the two or more sections, at least one image as a keeper image based on the comparison of the quality metric values.2. The non-transitory program storage device of claim 1 , wherein dividing the temporal sequence of images is based on detecting a scene change.3. The non-transitory program storage device of claim 1 , wherein the instructions further cause the one or more programmable control devices to:calculate a distance between images of the temporal sequence of images, wherein the ...

Grouping email messages into conversations

Exemplary methods, apparatuses, and systems determine that an indication that a received message was sent in response to another message is present in the received message, parse a stored message, in response to the indication being present, for at least a partial match between a subject of the received message and contents of a subject of the stored message, and for at least a partial match between sender and recipient participants of the received message and sender and recipient participants of the stored message, and display the received message as grouped with the stored message. A further exemplary feature includes parsing text of the received message for text that is redundant of text of the stored message, determining that a minimum threshold of consecutive matching characters has been reached, and displaying the received message with the consecutive matching characters at least partially hidden from view.

GROUPING EMAIL MESSAGES INTO CONVERSATIONS

Exemplary methods, apparatuses, and systems determine that an indication that a received message was sent in response to another message is present in the received message, parse a stored message, in response to the indication being present, for at least a partial match between a subject of the received message and contents of a subject of the stored message, and for at least a partial match between sender and recipient participants of the received message and sender and recipient participants of the stored message, and display the received message as grouped with the stored message. A further exemplary feature includes parsing text of the received message for text that is redundant of text of the stored message, determining that a minimum threshold of consecutive matching characters has been reached, and displaying the received message with the consecutive matching characters at least partially hidden from view. 1. A computer-implemented method of managing email message grouping comprising:determining, by the computer, that an indication that a received message was sent in response to another message is present in the received message;parsing, by the computer in response to the indication being present, a stored message for at least a partial match between a subject of the received message and subject of the stored message, and for at least a partial match between sender and recipient participants of the received message and sender and recipient participants of the stored message; anddisplaying, by the computer, the received message as grouped with the stored message determined by the parsing to have matching subject and participants to the received message.2. The computer-implemented method of claim 1 , further comprising:determining that the received message does not include reference header data or in-reply-to header data to identify the stored message, wherein the parsing is performed in response to the determination that the received message does not include ...

THERAPEUTIC ANTI-IGF1R COMBINATIONS

The present invention provides, in part, compositions including an anti-IGF1R antibody or antigen-binding fragment thereof and any one or more of cisplatin, pemetrexed, gemcitabine and/or irinotecan; optionally including or excluding a further chemotherapeutic agent, as well as methods of treating diseases, such as cancer, using such compositions. 1. A composition comprising an isolated antibody or antigen-binding fragment thereof comprising CDR-L1; CDR-L2; and CDR-L3 in a light chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 1;and/or,CDR-H1; CDR-H2; and CDR-H3 in a heavy chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 2;in association with gemcitabine and/or irinotecan.2. The composition of comprising dalotuzumab in association with gemcitabine and/or irinotecan.3. The composition of wherein the antibody or fragment is in association with gemcitabine and irinotecan.4. The composition of wherein said antibody or fragment is in association with a carrier.5. The composition of wherein the carrier comprises a buffer.6. The composition of wherein said antibody or fragment is in association with gemcitabine.7. The composition of wherein said antibody or fragment is in association with irinotecan.8. The composition wherein the antibody or fragment is an antibody.9. The composition of wherein the antibody is a humanized antibody.10. The composition wherein the antibody or fragment comprises a light chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 1; and/or a heavy chain immunoglobulin variable region comprising the amino acid sequence set forth in SEQ ID NO: 2.11. The composition of which further comprises a further chemotherapeutic agent.13. A method for treating or preventing a cancer whose growth claim 1 , survival and/or metastasis is mediated by IGF1R expression and/or activity in a subject comprising administering claim 1 , to ...

Therapeutic RNA for Advanced Stage Solid Tumor Cancers

This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy. 1. A method of treating a subject having a solid tumor cancer , comprising administering an effective amount of RNAs comprising RNA encoding an IL-12sc protein , RNA encoding an IL-15 sushi protein , RNA encoding an IFNα protein , and RNA encoding a GM-CSF protein , wherein the subject has failed , or become intolerant , resistant , or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.27-. (canceled)8. The method of claim 1 ,i) wherein the subject has anti-PD-1 and/or anti-PD-L1 resistant solid tumor cancer; orii) wherein the subject has a solid tumor cancer with acquired resistance or innate resistance to anti-PD-1 and/or anti-PD-L1 therapy: oriii) wherein the subject has a solid tumor cancer with innate resistance to anti-PD-1 and/or anti-PD-L1 therapy; oriv) wherein the subject has an advanced-stage, unresectable, or metastatic solid tumor ganger; orv) wherein the refractory or resistant cancer is one that does not respond to a specified treatment; orvi) wherein the refraction occurs from the very beginning of treatment; orvii) wherein the refraction occurs during treatment; orviii) wherein the cancer is resistant before treatment begins; orix) wherein the subject has a cancer that does not respond to the anti-programmed cell death 1 (PD-1) and/or anti-programmed cell death 1 ligand 1 (PD-L1) therapy; orx) wherein the subject has a cancer that is ...

METHODS FOR TREATING CANCER USING PI3K INHIBITOR AND MEK INHIBITOR

Methods of treating patients with cancer are provided, wherein the methods comprise administering to the patient an effective amount of a MEK inhibitor and an effective amount of a PI3K inhibitor. Compositions in which the MEK and PI3K inhibitors are combined also are described. 1. A method of treating cancer in a human patient , said method comprising administering to the patient an effective amount of (a) 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-y1)pyrido[2 ,3-d]pyrimidin-7(8H)-one or a pharmaceutically acceptable salt thereof , and (b) N—((S)-2 ,3-dihydroxypropyl)-3-(2-fluoro-4-iodo-phenylamino)isonicotinamide or a pharmaceutically acceptable salt thereof , wherein said cancer is selected from the group consisting of (i) KRAS or NRAS mutated non small cell lung cancer (NSCLC) , (ii) triple negative breast cancer (TNBC) , (iii) dual KRAS and PIK3CA mutated colorectal cancer (CRC) and (iv) BRAF mutated melanoma after progression on BRAF inhibitors.2. The method according to claim 1 , wherein the cancer is relapsed or refractory.3. The method according to claim 1 , wherein said effective amount is clinically proven safe.4. The method according to claim 1 , wherein the method comprises at least one cycle claim 1 , wherein the cycle is a period of 3 weeks claim 1 , wherein for each cycle the 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2 claim 1 ,3-d]pyrimidin-7(8H)-one or pharmaceutically acceptable salt thereof is administered at a daily dose of about 30 claim 1 , 50 claim 1 , 70 or 90 mg and the N—((S)-2 claim 1 ,3-dihydroxypropyl)-3-(2-fluoro-4-iodo-phenylamino)isonicotinamide or pharmaceutically acceptable salt thereof is administered at a daily dose of about 15 claim 1 , 30 claim 1 , 60 or 90 mg.5. The method according to claim 4 , wherein for each cycle the 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2 claim 4 ,3-d]pyrimidin-7(8H)-one or pharmaceutically acceptable salt thereof is administered at a daily dose of about 70 mg and the N—((S)-2 claim 4 ...

Automated Selection Of Keeper Images From A Burst Photo Captured Set

Systems and methods for improving automatic selection of keeper images from a commonly captured set of images are described. A combination of image type identification and image quality metrics may be used to identify one or more images in the set as keeper images. Image type identification may be used to categorize the captured images into, for example, three or more categories. The categories may include portrait, action, or “other.” Depending on the category identified, the images may be analyzed differently to identify keeper images. For portrait images, an operation may be used to identify the best set of faces. For action images, the set may be divided into sections such that keeper images selected from each section tell the story of the action. For the “other” category, the images may be analyzed such that those having higher quality metrics for an identified region of interest are selected. 1. A non-transitory program storage device , readable by a programmable control device and comprising instructions stored thereon to cause one or more programmable control devices to:obtain a temporal sequence of images of a scene;detect, by an image processor, if each of the images contains primarily faces by calculating a total face size for each image and comparing the total face size of the image to a total size of the image;process, by the image processor, each of the obtained images to obtain for each image at least one quality metric value;select one or more images from the sequence of images as keeper images, wherein the selection is made at least in part based on whether each image contains primarily faces and on the at least one quality metric value for the image; andretain the one or more keeper images in a memory.2. The non-transitory program storage device of claim 1 , wherein the instructions to cause the one or more programmable control devices to process comprise instructions to cause the one or more programmable control devices to determine claim 1 , for ...

Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers

This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy. 1. A method of treating a subject having a solid tumor cancer , comprising administering an effective amount of RNAs comprising RNA encoding an IL-12sc protein , RNA encoding an IL-15 sushi protein , RNA encoding an IFNα protein , and RNA encoding a GM-CSF protein , and an anti-programmed cell death 1 (PD-1) antibody , wherein the subject has failed , or become intolerant , resistant , or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.2. The method of claim 1 , wherein the subject has failed claim 1 , or become intolerant claim 1 , resistant claim 1 , or refractory to an anti-programmed cell death 1 (PD-1) therapy.3. The method of claim 1 , wherein the subject has failed claim 1 , or become intolerant claim 1 , resistant claim 1 , or refractory to an anti-programmed cell death 1 ligand 1 (PD-L1) therapy.4. The method of claim 1 , wherein the subject has failed an anti-programmed cell death 1 (PD-1) therapy or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.5. The method of claim 1 , wherein the subject has become intolerant to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.6. The method of claim 1 , wherein the subject has become resistant to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.7. The method of claim 1 , wherein the subject has become ...

Identifying Dominant and Non-Dominant Images in a Burst Mode Capture

For cameras that capture several images in a burst mode, some embodiments of the invention provide a method that presents one or more of the captured images differently than the remaining captured images. The method identifies at least one captured image as dominant image and at least another captured image as a non-dominant image. The method then displays each dominant image different from each non-dominant image in a concurrent presentation of the images captured during the burst mode. The dominant images may appear larger than non-dominant images, and/or appear with a marking that indicates that the images are dominant. 1. A method of presenting images captured during a single burst mode capture , the method comprising:capturing a plurality of images in a single burst mode capture;designating a set of the captured images as dominant images; andpresenting the set of dominant images different from each other non-dominant image in a presentation of the images captured during the single burst mode capture.2. The method of claim 1 , wherein the presenting comprising making each dominant image appear larger than each other non-dominant image in the presentation.3. The method of claim 1 , wherein the presenting comprises displaying each dominant image with a marking that indicates that the image is a dominant image.4. The method of further comprising:in response to a user's selection of the marking, designating the dominant image as a non-dominant image; andpresenting the designated dominant image without the marking in the presentation.5. The method of claim 1 , wherein the presenting comprises displaying each non-dominant image with a marking that indicates that the image is a non-dominant image.6. The method of further comprising:in response to a user's selection of the marking, designating the non-dominant image as a dominant image; andpresenting the designated non-dominant image without the marking in the presentation.7. The method of further comprising providing ...

Identifying Dominant and Non-Dominant Images in a Burst Mode Capture

For cameras that capture several images in a burst mode, some embodiments of the invention provide a method that presents one or more of the captured images differently than the remaining captured images. The method identifies at least one captured image as dominant image and at least another captured image as a non-dominant image. The method then displays each dominant image different from each non-dominant image in a concurrent presentation of the images captured during the burst mode. The dominant images may appear larger than non-dominant images, and/or appear with a marking that indicates that the images are dominant. 1capturing a plurality of images in a single burst mode capture;designating a set of the captured images as dominant images; andpresenting the set of dominant images different from each other non-dominant image in a presentation of the images captured during the single burst mode capture.. A method of presenting images captured during a single burst mode capture, the method comprising: This application is a continuation of U.S. application Ser. No. 14/097,670, filed Dec. 5, 2013, which claims priority to U.S. Provisional Application Ser. No. 61/829,990, filed May 31, 2013, which are incorporated herein by reference in their entireties.With the advent of digital photography, a person no longer has to buy film to take pictures. In addition, the person does not have to take the film to a film developer, wait some time to have it processed, and then return to the developer to finally look at the finished pictures. Nowadays, a person can just snap a picture with a digital camera and look at the picture. If the person does not like the picture, he or she can take another one. Also, people can take pictures with all kinds of devices. Examples of such devices include digital cameras, smart phones, tablets, laptops, etc.The problem today is not so much about the convenience in taking pictures or the wait to have the pictures ready. Rather, it is more and ...

Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers

This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.

Combination therapy using an anti-egfr agent(s) and igf-1r specific antibodies

A combination of an IGF -1 R antagonist and an antiproliferative drug is described. A preferred combination of an IGF-1r antibody and an antiproliferative drug belonging to the EGFR-inhibitor class, preferably erlotinib, useful for the treatment of tumours, including IGF -IR and lor EGFR mediated or dependent tumours, is disclosed.

Method and apparatus for automatically providing network services

An embodiment of the invention is directed to a method and apparatus for automatically providing network services in a way that improves upon the prior art. Systems implementing aspects of the invention can, for instance, provide developers with a mechanism for creating Web Services without having to write low-level SOAP, XML, or WSDL code. The system utilizes a rule-based approach to provide a mechanism for dynamically reconfiguring the system with requiring redeployment of the entire system.

Method and apparatus for automatically providing network services

An embodiment of the invention is directed to a method and apparatus for automatically providing network services in a way that improves upon the prior art. Systems implementing aspects of the invention can, for instance, provide developers with a mechanism for creating Web Services without having to write low-level SOAP, XML, or WSDL code. The system utilizes a rule-based approach to provide a mechanism for dynamically reconfiguring the system with requiring redeployment of the entire system.

Therapeutic anti-igf1r combinations

The present invention provides, in part, compositions including an anti-IGF1R antibody or antigen-binding fragment thereof and any one or more of cisplatin, pemetrexed, gemcitabine and/or irinotecan; optionally including or excluding a further chemotherapeutic agent, as well as methods of treating diseases, such as cancer, using such compositions.

Method and apparatus for automatically providing network services

An embodiment of the invention is directed to a method and apparatus for automatically providing network services in a way that improves upon the prior art. Systems implementing aspects of the invention can, for instance, provide developers with a mechanism for creating Web Services without having to write low-level SOAP, XML, or WSDL code. The system utilizes a rule-based approach to provide a mechanism for dynamically reconfiguring the system with requiring redeployment of the entire system.

Automated selection of keeper images from a burst photo captured set

Abstract Systems and methods for improving automatic selection of keeper images from a commonly captured set of images are described. A combination of image type identification and image quality metrics may be used to identify one or more images in the set as keeper images. Image type identification may be used to categorize the captured images into, for example, three or more categories. The categories may include portrait, action, or "other." Depending on the category identified, the images may be analyzed differently to identify keeper images. For portrait images, an operation may be used to identify the best set of faces. For action images, the set may be divided into sections such that keeper images selected from each section tell the story of the action. For the "other" category, the images may be analyzed such that those having higher quality metrics for an identified region of interest are selected.

Method and system for optimizing the number of word line segments in a segmented MRAM array

A method and system for programming and reading a magnetic memory is disclosed. The magnetic memory includes a plurality of selectable word line segments and a plurality of magnetic storage cells corresponding to each word line segment. The method and system include reading the magnetic storage cells corresponding to a word line segment to determine a state of each magnetic storage cell. The method and system also include writing data to a portion of the magnetic cells corresponding to the word line segment after the reading. The method and system also include rewriting the state to each of a remaining portion of the magnetic storage cells corresponding to the word line segments at substantially the same time as the portion of the magnetic cells are written.

Method and system for providing a programmable current source for a magnetic memory

Sense amplifier for single-ended data sensing

Methods for treating cancer using pi3k inhibitor and mek inhibitor

Methods of treating patients with cancer are provided, wherein the methods comprise administering to the patient an effective amount of a MEK inhibitor and an effective amount of a PI3K inhibitor. Compositions in which the MEK and PI3K inhibitors are combined also are described.

Methods for treating cancer using pi3k inhibitor and mek inhibitor.

Se proporcionan métodos de tratamiento de pacientes con cáncer, en donde los métodos comprenden administrar al paciente una cantidad eficaz de un inhibidor de MEK y una cantidad eficaz de un inhibidor de PI3K. Se describen también composiciones en las que se combinan los inhibidores de MEK y PI3K.

Arn terapeutico para tumores solidos cancerigenos en etapa avanzada.

Esta descripción se refiere al campo de los ARN terapéuticos para el tratamiento de sujetos en los que ha fracasado, o se han vuelto intolerantes, resistentes, o refractarios a, una terapia anti-muerte celular programada 1 (PD-1) o anti-ligando 1 de muerte celular programada 1 (PD-L1), incluyendo terapia innata y adquirida PD-1 y/o PD-L1, así como en sujetos con tumor sólido cancerígeno en etapa avanzada, no extirpable, o metastásico con o sin fracaso, intolerancia, resistencia, o refractariedad a una terapia antimuerte celular programada 1 (PD-1) o anti-ligando 1 de muerte celular programada 1 (PD-L1).

Application deployment

The present disclosure generally relates deploying an application. Some techniques described herein occur during compile time while executable code is being generated from source code. In one example, the executable code causes different operations in an application to be assigned to different compute systems such that particular operations are required to be executed on particular compute systems. The executable code may further include bridges that assist data being transmitted between different compute systems, the bridges generated during compile time. In another example, the executable code causes data to be sent to a recording service during execution of an application. The recording service, though not included in the source code before compile time, is configured to receive copies of data transmitted on a compute system including the recording service. The recording service may also be configured to receive metadata corresponding to operations executed on the compute system.

Playback engine

Application deployment

The present disclosure generally relates deploying an application. Some techniques described herein occur during compile time while executable code is being generated from source code. In one example, the executable code causes different operations in an application to be assigned to different compute systems such that particular operations are required to be executed on particular compute systems. The executable code may further include bridges that assist data being transmitted between different compute systems, the bridges generated during compile time. In another example, the executable code causes data to be sent to a recording service during execution of an application. The recording service, though not included in the source code before compile time, is configured to receive copies of data transmitted on a compute system including the recording service. The recording service may also be configured to receive metadata corresponding to operations executed on the compute system.

Playback engine

The present disclosure generally relates to capturing multiple types of data during execution of an application, the multiple types of data including data associated with messages published by nodes and metadata corresponding to execution of nodes. The multiple types of data are then stored with associated message identifiers to efficiently capture all data needed for playback. In some examples, such techniques allow for deterministic playback, even when nodes are concurrently operating on different compute systems.

Data-transmission connector

Data transmission connector

Therapeutic rna for advanced stage solid tumor cancers

This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-l and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.

Therapeutic rna for advanced stage solid tumor cancers

This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-l and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.

Playback engine

The present disclosure generally relates to capturing multiple types of data during execution of an application, the multiple types of data including data associated with messages published by nodes and metadata corresponding to execution of nodes. The multiple types of data are then stored with associated message identifiers to efficiently capture all data needed for playback. In some examples, such techniques allow for deterministic playback, even when nodes are concurrently operating on different compute systems.

Identifying dominant and non-dominant images in a burst mode capture

For cameras that capture several images in a burst mode, some embodiments of the invention provide a method that presents one or more of the captured images differently than the remaining captured images. The method identifies at least one captured image as dominant image and at least another captured image as a non-dominant image. The method then displays each dominant image different from each non-dominant image in a concurrent presentation of the images captured during the burst mode. The dominant images may appear larger than non-dominant images, and/or appear with a marking that indicates that the images are dominant.